{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:31:35Z","timestamp":1649208695971},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00108-016-0035-9","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T13:22:29Z","timestamp":1458566549000},"page":"349-361","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis"],"prefix":"10.1007","volume":"57","author":[{"given":"J.","family":"Schodrowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Seipelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Adibi-Sedeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Eienbr\u00f6ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Tackenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"35_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO et al (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46.","journal-title":"BMC Neurol"},{"key":"35_CR2","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H-C Diener","year":"2012","unstructured":"Diener H-C, Deutsche Gesellschaft f\u00fcr Neurologie Kommission Leitlinien (2012) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Stuttgart u.\u202fa.: Thieme"},{"key":"35_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00063030-200115060-00003","volume":"15","author":"B Tackenberg","year":"2001","unstructured":"Tackenberg B, Hemmer B, Oertel WH et al (2001) Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs 15:369\u2013378","journal-title":"BioDrugs"},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","volume":"65","author":"NP Robertson","year":"1998","unstructured":"Robertson NP, Deans J, Compston DA (1998) Myasthenia gravis: a population based epidemiological study in Cambridgeshire. England J Neurol Neurosurg Psychiatry 65:492\u2013496","journal-title":"England. J Neurol Neurosurg Psychiatry"},{"key":"35_CR5","doi-asserted-by":"crossref","unstructured":"Liyanage Y, Hoch W, Beeson D (2002) The agrin\/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25:4\u201316","DOI":"10.1002\/mus.1218"},{"key":"35_CR6","doi-asserted-by":"crossref","unstructured":"Sommer N, Tackenberg B, Hohlfeld R (2008) The immunopathogenesis of myasthenia gravis. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18631843 . Handb Clin Neurol. 91:169\u2013212","DOI":"10.1016\/S0072-9752(07)01505-9"},{"key":"35_CR7","doi-asserted-by":"crossref","unstructured":"Conti-Fine BM (2008) CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 1132:193\u2013209","DOI":"10.1196\/annals.1405.042"},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/NCC:3:3:189","volume":"3","author":"D Lacomis","year":"2005","unstructured":"Lacomis D (2005) Myasthenic crisis. Neurocrit Care 3:189\u2013194","journal-title":"Neurocrit Care"},{"issue":"7","key":"35_CR9","first-page":"420","volume":"104","author":"C Schneider-Gold","year":"2007","unstructured":"Schneider-Gold C, Toyka KV (2007) Myasthenia gravis: Pathogenese und Immuntherapie. Dtsch Arztebl 104(7):420\u2013426","journal-title":"Dtsch Arztebl"},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.ophtha.2009.04.039","volume":"116","author":"KI Chatzistefanou","year":"2009","unstructured":"Chatzistefanou KI, Kouris T, Iliakis E et al (2009) The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology 116:2236\u20132243","journal-title":"Ophthalmology"},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/WNO.0b013e3182224b92","volume":"31","author":"EL Singman","year":"2011","unstructured":"Singman EL, Matta NS, Silbert DI (2011) Use of the Cogan lid twitch to identify myasthenia gravis. J\u00a0Neuroophthalmol 31:239\u2013240","journal-title":"J Neuroophthalmol"},{"key":"35_CR12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0031-1279757","volume":"38","author":"F Schumm","year":"2011","unstructured":"Schumm F, Henze T (2011) Symptomatische Therapie bei Myasthenia Gravis und anderen neuromuskul\u00e4ren \u00dcbertragungsst\u00f6rungen. Aktuelle Neurologie 38:178\u2013189","journal-title":"Aktuelle Neurologie"},{"key":"35_CR13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK (1998) Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 97:370\u2013373","journal-title":"Acta Neurol Scand"},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"35_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"11","author":"JM Heckmann","year":"2011","unstructured":"Heckmann JM, Rawoot A, Bateman K et al (2011) A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 11:97","journal-title":"BMC Neurol"},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","volume":"76","author":"I Cortese","year":"2011","unstructured":"Cortese I, Chaudhry V, So YT et al (2011) Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 76:294\u2013300","journal-title":"Neurology"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00041552-200211000-00012","volume":"11","author":"GM Blake","year":"2002","unstructured":"Blake GM, Fogelman I (2002) Bone densitometry, steroids and osteoporosis. Curr Opin Nephrol Hypertens 11:641\u2013647","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","volume":"65","author":"S Vernino","year":"2005","unstructured":"Vernino S, Salomao DR, Habermann TM et al (2005) Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 65:639\u2013641","journal-title":"Neurology"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B et al (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56:97\u201399","journal-title":"Neurology"},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/2047-783X-14-8-364","volume":"14","author":"F Hanisch","year":"2009","unstructured":"Hanisch F, Wendt M, Zierz S (2009) Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis \u2013 a long-term prospective open-label study. Eur J Med Res 14:364\u2013366","journal-title":"Eur J Med Res"},{"key":"35_CR21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers J et al (2010) Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 41:593\u2013598","journal-title":"Muscle Nerve"},{"key":"35_CR22","first-page":"617","volume":"2","author":"R Hohlfeld","year":"1993","unstructured":"Hohlfeld R, Goebels N, Engel AG (1993) Cellular mechanisms in inflammatory myopathies. Baillieres Clin Neurol 2:617\u2013635","journal-title":"Baillieres Clin Neurol"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-2004-829596","volume":"24","author":"A Jaretzki","year":"2004","unstructured":"Jaretzki A, Steinglass KM, Sonett JR (2004) Thymectomy in the management of myasthenia gravis. Semin Neurol 24:49\u201362","journal-title":"Semin Neurol"},{"key":"35_CR24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","volume":"48","author":"F Schumm","year":"1985","unstructured":"Schumm F, Wietholter H, Fateh-Moghadam A et al (1985) Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 48:332\u2013337","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"35_CR25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","volume":"57","author":"MI Leite","year":"2005","unstructured":"Leite MI, Strobel P, Jones M et al (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57:444\u2013448","journal-title":"Ann Neurol"},{"key":"35_CR26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A et al (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62:156\u2013162","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"35_CR27","first-page":"CD008111","volume":"10","author":"G Cea","year":"2013","unstructured":"Cea G, Benatar M, Verdugo RJ et al (2013) Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10:CD008111","journal-title":"Cochrane Database Syst Rev"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.athoracsur.2008.11.040","volume":"87","author":"DM Meyer","year":"2009","unstructured":"Meyer DM, Herbert MA, Sobhani NC et al (2009) Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg 87:385\u2013390, discussion 390\u2013381","journal-title":"Ann Thorac Surg"},{"key":"35_CR29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/09638280600926702","volume":"29","author":"EH Cup","year":"2007","unstructured":"Cup EH, Pieterse AJ, Knuijt S et al (2007) Referral of patients with neuromuscular disease to occupational therapy, physical therapy and speech therapy: usual practice versus multidisciplinary advice. Disabil Rehabil 29:717\u2013726","journal-title":"Disabil Rehabil"},{"issue":"United States","key":"35_CR30","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.apmr.2007.07.024","volume":"88","author":"EH Cup","year":"2007","unstructured":"Cup EH, Pieterse AJ, Ten B-PJM et al (2007) Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil 88(United States):1452\u20131464","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-016-0035-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0035-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:17:44Z","timestamp":1558585064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-016-0035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s00108-016-0035-9","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}